Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2021

01-06-2021 | ABSTRACT SET

Abstracts 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)

Published in: International Journal of Clinical Pharmacy | Issue 3/2021

Login to get access

Excerpt

Background Exposure to anticholinergic and sedative drugs have been associated with adverse health outcomes in the elderly population, which can be measured in an individual patient using Drug Burden Index (DBI). Higher DBI values were associated with poorer cognitive and physical performance, which may negatively influence cardiovascular disease (CVD) therapy outcomes. …
Metadata
Title
Abstracts 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 3/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-021-01269-4

Other articles of this Issue 3/2021

International Journal of Clinical Pharmacy 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine